Program
Magnesium Chloride
Also written as “Custodiol” and “Nalmefene + 0.94% MgCl2”.
Its studies are mostly in Opiate Overdose · Diabetes Mellitus, Type 1 · Aortic Valve Disease · Heart Failure · Coronary Artery Disease, led by 4 companies.
Drug pageMagnesium Chloride: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dr. F. Köhler Chemieits history only | 41 open or running | phase 3since Feb 14, 2014 | Sep 29, 2011 | Jan 2027phase 2 · NCT06032195 |
| Eli Lilly | 10 open or running | phase 1since Sep 28, 2021 | Sep 28, 2021 | none ahead |
| Knoa Pharmaits history only | 10 open or running | phase 1since Apr 15, 2026 | Apr 15, 2026 | none ahead |
| Relox Medicalits history only | 10 open or running | phase 3since Jun 30, 2009 | Jun 30, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 28, 2021First study: phase 1 study in Diabetes Mellitus, Type 1First studyNCT05067270 · 40 enrolled · Germany
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Eli Lilly leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05067270Diabetes Mellitus, Type 1 · Germany | 1 | Completed | Dec 6, 2021 | 40 |
How it is read
Names in the registry
- “Custodiol”, 4 entries
- “Nalmefene + 0.94% MgCl2”, 2 entries
- “Magnesium Chloride”, 2 entries
Conditions, from the studies’ own filings
- Opiate Overdose, 1 study
- Diabetes Mellitus, Type 1, 1 study
- Aortic Valve Disease, 1 study
- Heart Failure, 1 study
- Coronary Artery Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.